Business Wire

Q4 Inc. Announces Solid First Quarter 2023 Results

Share

Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), a leading capital markets access platform, today announced its financial results for the three-month period ended March 31, 2023. QFOR reports in U.S. dollars and in accordance with International Financial Reporting Standards (“IFRS”).

“I am proud of the team's ability to continue delivering organic growth in Q1 despite muted capital markets activity,” said Darrell Heaps, Founder and Chief Executive Officer. “Over half of our bookings were expansions with existing clients who continue adding new modules to their Q4 stack, such as engagement analytics, CRM and ESG add-ons. The result deepens our client relationships, drives loyalty and expands margins.”

First Quarter 2023 Financial Highlights

  • Revenue of $14.5 million, up 4% compared with $13.9 million in Q1 2022;
  • Annual recurring revenue1 up 5.3% year-over-year, to $55.6 million;
  • ARPA up 11% year-over-year to $20,411 driven primarily by existing clients adding new subscriptions;
  • Gross margin up 802 basis points year over year to 65.4%;
  • Adjusted EBITDA2 of $(4.5) million, a 37% improvement compared with $(7.1) million in Q1 2022;
  • Net loss of $(7.1) million, or $(0.18) per share; and
  • As of March 31, 2023, the Company had $46.3 million in available liquidity, including $23.8 million in cash and cash equivalents, and an undrawn credit facility of $22.5 million.

“We ended Q1 with gross margins on target, reaching 65.4%, commented Darrell Heaps. This accomplishment is due to our successful execution on several initiatives, including, our virtual events platform, our fixed data contracts, the adoption of the web management app on Capital Connect, and the build up of our LATAM operations. These structural changes are permanent and sustainable and will have a lasting impact for continued gross margin expansion through the remainder of the year, exiting 2023 in the mid-70’s.”

Operational Highlights

  • Over 1,800 clients and agencies active on the Q4 Capital Connect Platform in Q1, gaining new and unique insights while improving workflow;
  • Launched the Engagement Analytics suite, an innovative benchmarking and investor targeting tool gleaned through millions of investor interactions;
  • Initiated the integration of Generative AI across our products, proprietary data and real time analytics;
  • Enhanced CRM with email integration and new mobile app, delivering expanded functionality that will strengthen outreach strategies for IR professionals;
  • More than 100,000 new Q4 Accounts created during the first quarter, up more than 50% since the end of 2022. To date, more than 286,000 investors have signed up for this platform service;
  • More than 16 million unique investors accessed Q4’s network of IR websites each month during the quarter; and
  • Announced a partnership with Novisto that will enable companies to build their ESG narrative to be delivered through Q4’s innovative platform, providing clients with an ESG data management solution to enhance their sustainability reporting.

“Across the business, we continue pulling on multiple levers to accelerate towards profitable growth,“ said Donna de Winter, Chief Financial Officer. “We have taken deliberate actions to significantly lower our operating expenses, improving our visibility to both positive EBITDA and cash flow in 2023.”

Specifically, the Company is accelerating the implementation of the following strategic actions:

  • Further traction in expansion sales and marketing, focused on introducing data analytics and enhanced CRM to existing clients globally;
  • The expansion of its Latin America operations, aligning global delivery capabilities to best partner with clients; and
  • Technology enabled scale in our core offerings allowing for labour reductions.

These actions are expected to lower annual operating expenses by at least $6.0 million with improvements expected to surface in Q2 and continue throughout the second half of 2023.

Normal Course Issuer Bid

The Company renewed its Normal Course Issuer Bid (“NCIB”) on March 29th, providing flexibility to repurchase up to 2,134,343 shares over the next twelve months. During the previous NCIB which ended in Q1, the Company repurchased and canceled 379,400 shares at an average price of $2.52.

Webcast Information

Q4 will host a webcast to discuss the Company's financial results at 9:30 am ET on Monday, May 15, 2023. Participants can register in advance or access the webcast live at https://events.q4inc.com/attendee/223412388. Supplemental materials will be available at least fifteen minutes prior to the start of the event. A replay of the webcast will be available at investors.q4inc.com shortly after the event concludes.

Audience questions will be taken real-time via the Q4 Platform. Investors can also submit their questions in advance to ir@q4inc.com or via our IR website. We will do our best to respond to your questions either on the webcast, if time permits or shortly thereafter. We appreciate your interest.

Q4's unaudited interim consolidated financial statements and management's discussion and analysis for the three months ended March 31, 2023 will be available on Q4's IR website and will be filed on SEDAR at www.sedar.com.

First Quarter 2023 Results

Selected Financial Measures

Revenue

 

 

 

 

 

Three Months Ended March 31,

 

2023

2022

Change

Change

(USD in thousands)

$

$

$

%

Capital markets platform

13,182

12,864

318

2.5%

Platform services

1,298

1,063

235

22.1%

Other

19

18

1

 

Total revenue

14,499

13,945

554

4.0%

Gross profit

9,486

8,006

1,480

18.5%

Percentage of total revenue

65.4%

57.4%

 

 

Key Performance Indicators

 

March 31, 2023

March 31, 2022

Change

Change

(in USD)

$

$

$

%

Annual Recurring Revenue (in millions)

$

55.6

$

52.8

$

2.8

5.3%

Average Recurring Revenue per Account

$

20,411

$

18,404

$

2,007

10.9%

Results of Operations

The following table outlines our consolidated statement of loss and comprehensive loss for the three months ended March 31, 2023 and 2022:

 

Three Months Ended

 

March 31,

 

2023

2022

(USD in thousands)

$

$

Revenue

14,499

13,945

Direct cost of revenue

5,013

5,939

Gross profit

9,486

8,006

Operating Expenses

 

 

Sales and marketing

4,880

5,144

Research and development

4,299

4,130

General and administrative

5,526

5,771

Depreciation and amortization

941

901

Foreign exchange loss (gain)

7

(597)

Other expenses

324

280

Total operating expenses

15,977

15,629

Loss from operations

(6,491)

(7,623)

Finance expenses

12

21

Finance income

(92)

(3)

Impairment loss

634

Gain on derivative financial instruments

(1,104)

Loss before income taxes

(7,045)

(6,537)

Income taxes

53

60

Net loss

(7,098)

(6,597)

Other comprehensive income (loss)

 

 

Foreign exchange gain (loss) on foreign operations

22

(11)

Net loss and comprehensive loss

(7,076)

(6,608)

Basic and diluted loss per share

(0.18)

(0.17)

Weighted average number of common shares outstanding - basic and diluted

39,919

39,624

Key Balance Sheet Information

 

March 31, 2023

December 31, 2022

Change

Change

(USD in thousands)

$

$

$

%

Cash and cash equivalents

11,589

21,536

$(9,947)

(46.2)%

Short-term investments

12,222

7,607

4,615

60.7%

Total assets

67,402

73,832

(6,430)

(8.7)%

Total liabilities

29,574

29,459

115

0.4%

Total long-term liabilities

9,181

8,210

971

11.8%

Non-IFRS Measures and Reconciliation of Non-IFRS Measures

This press release makes reference to certain non-IFRS financial measures including key performance indicators used by management and typically used by our competitors with software-as-a-service (“SaaS”) business models. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore not necessarily comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS financial measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. These non-IFRS financial measures and industry metrics are used to provide investors with supplemental measures of our operating performance and liquidity and thus highlight trends in our business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS financial measures and industry metrics, in the evaluation of similar companies. Management also uses non-IFRS financial measures and industry metrics in order to facilitate operating performance comparisons from period to period, the preparation of annual operating budgets and forecasts and to determine components of executive compensation.

EBITDA and Adjusted EBITDA

We define EBITDA as net loss, adjusted for depreciation and amortization, finance expenses, finance income and income taxes. Adjusted EBITDA is a supplemental measure used by management to assess our financial and operating performance without regards to financing methods or capital structure. Adjusted EBITDA represents EBITDA, adjusted for the following: share-based compensation, unrealized foreign exchange (gain)/ loss, (gain)/loss on derivative financial instruments, severance and related costs, impairment loss, and management fee and other costs. We believe EBITDA and Adjusted EBITDA, two non-IFRS financial measures, are useful in assessing our operating cash flows as they eliminate the effects of non-cash expenses and one-time or non-recurring items recorded in the statements of loss and comprehensive loss. The Company’s definition of EBITDA and Adjusted EBITDA may be different than similarly titled measures used by other companies. The following table reconciles Adjusted EBITDA to net loss for the periods

 

Three Months Ended

 

March 31,

 

2023

2022

(USD in thousands)

$

$

Net loss

(7,098

)

(6,597

)

Depreciation and amortization

941

 

901

 

Finance expenses(1)

12

 

21

 

Finance income

(92

)

(3

)

Income taxes

53

 

60

 

EBITDA

(6,184

)

(5,618

)

Other adjustments

 

 

Share-based compensation expense(2)

426

 

148

 

Unrealized foreign exchange loss (gain)(3)

7

 

(597

)

Gain on derivative financial instruments(4)

 

(1,104

)

Impairment loss

634

 

 

Severance and related costs(5)

447

 

 

Management fee and other costs(6)

212

 

22

 

Adjusted EBITDA

(4,458

)

(7,149

)

EBITDA loss per share

(0.15

)

(0.14

)

Adjusted EBITDA loss per share

(0.11

)

(0.18

)

Note:

(1)

 

Finance expenses are primarily related to interest and accretion of financial liabilities.

(2)

 

Share-based compensation includes non-cash expenditures recognized in connection with the issuance of options under our Legacy Equity Incentive Plan ("LEIP") to certain employees and directors. Options granted under the LEIP have become options under our Omnibus Equity Incentive Plan (the “Omnibus Plan”) in connection with the 2021 IPO. This amount also includes the restricted share units ("RSUs"), performance share units ("PSUs") and deferred share units ("DSUs") granted under the Omnibus Plan.

(3)

 

These adjustments represent the change in the value of foreign currency denominated transactions that are recorded in financial statements prior to the settlement of invoices.

(4)

 

These adjustments represent fair value adjustments relating to outstanding warrants.

(5)

 

Represents severance and related expenses included in G&A and other expenses.

(6)

 

These expenses relate to professional, consulting, advisory, and other fees that are non-recurring.

Free Cash Flow

Free cash flow represents cash flow from/(used in) operating activities, less additions to property and equipment. We use free cash flow, a non-IFRS financial measure, to assess the amount of cash available for dividend payments, debt repayment and other investing and financing activities. We believe that this information is useful to certain investors and analysts to evaluate the Company’s performance with respect to its operating cash flow capacity to meet non-discretionary outflows of cash. The following table reconciles our cash flow from/(used in) operating activities to free cash flow:

 

Three Months Ended

 

March 31,

 

2023

2022

(USD in thousands)

$

$

Cash flow from (used in) operating activities

(5,957)

(7,592)

Purchases of property and equipment

(42)

(279)

Free cash flow

(5,999)

(7,871)

Key Performance Indicators

This press release also makes reference to “Annual Recurring Revenue” or “ARR” and “Annual Recurring Revenue Per Account” or “ARPA”, which are key performance indicators we use to help us evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. Our key performance indicators may be calculated in a manner different from similar key performance indicators used by other companies. Definitions of these key performance indicators can be found under the heading “Key Performance Indicators” in the Company’s management’s discussion and analysis for the three months ended March 31, 2023 and 2022.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. In some cases, forward-looking information generally can be identified by the use of terminology such as “expect”, “continue”, “anticipate”, “intend”, “aim”, “plan”, “believe”, “budget”, “estimate”, “forecast”, “foresee”, “close to”, “target” or negative versions thereof and similar expressions.

This forward-looking information relates to our future financial outlook and anticipated events or results and includes, but is not limited to, information regarding: the Company’s financial position, financial results, business strategy, performance, achievements, growth strategies; the Company’s budgets, operations, and taxes; judgments and estimates impacting our financial statements; the market in which the Company operates; industry trends and the Company’s competitive position; expansion of the Company’s product offerings; trends in research and development ("R&D") expenses and general and administrative ("G&A") expenses, each as a percentage of revenue; planned decreases in sales and marketing and R&D activities; the timing and pace for achieving profitability; and expectations regarding the growth of the Company’s customer base, revenue and revenue generation potential.

Forward-looking information is based on certain assumptions, expectations and projections, and analyses made by the Company in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying assumptions, expectations, estimates and assumptions will prove to be correct. Certain assumptions underlying the forward-looking information in this MD&A include: our ability to continue investing in infrastructure to support our growth and brand recognition; our ability to continue maintaining and enhancing our technological infrastructure and the functionality of our platform; our ability to develop and implement new product offerings; our ability to capitalize on growth opportunities and implement our growth strategy; our ability to build our market share and enter new geographies; the total addressable market for our products; our ability to retain key personnel; our ability to maintain existing customer relationships and to continue to expand our clients’ use of our platform and products; our ability to maintain existing relationships on similar terms with our current service providers, suppliers, channel partners and other third parties; our ability to maintain and expand our geographic scope; our ability to execute on our expansion plans; our ability to obtain financing on acceptable terms or at all; the impact of competition; the changes and trends in our industry or the global economy; changes in laws, rules, regulations, and global standards; and that the risks and uncertainties noted below will not materialize.

Given these risks or uncertainties, investors are cautioned not to place undue reliance on forward-looking information, including any financial outlook. Any forward-looking information that is contained in this MD&A speaks only as of the date of such statement, and the Company undertakes no obligation to update any forward-looking information or to publicly announce the results of any revisions to any of those statements to reflect future events or developments, except as required by applicable securities laws. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data. The opinions, estimates or assumptions referred to above are described in greater detail in "Summary of Factors Affecting our Performance" and should be considered carefully by prospective investors.

Additional information relating to Q4, can be found on SEDAR under the Company’s profile at www.sedar.com.

About Q4 Inc.

Q4 Inc. (TSX: QFOR) is a leading capital markets access platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently connect, communicate, and engage with each other.

The Q4 Platform facilitates interactions across the capital markets through IR website products, virtual events solutions, engagement analytics, investor relations CRM, shareholder and market analysis, surveillance, and ESG tools. The Q4 Platform is the only holistic capital markets platform that digitally drives connections, analyzes impact, and targets the right engagement to help public companies work faster and smarter.

The company is a trusted partner to more than 2,650 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.

Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.

__________________________
1 Annual recurring revenue or “ARR” is a key performance indicator. See “Key Performance Indicators”
2 Adjusted EBITDA is a non-IFRS measure. See “Non-IFRS Measures and Reconciliation of Non-IFRS Measures”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors
Edward Miller
Director, Investor Relations
(437) 291-1554
ir@q4inc.com

Media
Heather Noll
Corporate Communications Manager
media@q4inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB

Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 15:00:00 EET | Press release

Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment. “With this Series C raise and the upcoming build-out

Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become

Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release

Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m

Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year2.12.2025 14:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. “Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the industry to stay a step ahead of threat actors and hugely beneficial to keeping society as we know it safe from disruptions.” Since

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye